Insight
Capital generation and return metrics in Europe
Despite its ease of calculation, capital generation and return—measured as a change in eligible own funds—may not be the most useful metric.
A multi-year look at the cost burden of cancer care
10 April 2017
Total spending for cancer care in the U.S. has been reported to be about $125 billion in 2010 and is projected to increase to between 27% and 39% by 2020. A cancer diagnosis translates into significant spending that may continue for years for both payers and patients. This report characterizes the costs to cancer patients and their health plans for three cancers: breast, lung, and colorectal.
This report was commissioned by Pfizer, Inc.
About the Author(s)
INSIGHT